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Introduction: 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) can reveal the metabolic activity of
malignant tumors. Recent advances gained from molecular studies suggest that tumor biology can be a good
predictor of prognosis in breast cancer. We compared the ability of maximum standardized uptake values (SUVmax)
derived by FDG-PET with tumor burden in predicting tumor recurrence for patients with breast cancer.
Methods: 496 patients with breast cancer who underwent preoperative FDG-PET between April 2004 and May 2009 were
retrospectively identified. SUVmax was obtained by FDG-PET, and the cutoff point was defined using a time-dependent
receiver operating characteristic curve for recurrence-free survival (RFS). The primary endpoint was RFS.
Results: In multivariate analysis for RFS, SUVmax carried independent prognostic significance (hazard ratio, 2.39; 95%
confidence interval, 1.20 to 4.76; P = 0.012). When the patients were classified into four groups according to the combined
factors of tumor size (≤2 cm versus >2 cm) and SUVmax (<4 versus ≥4), RFS differed significantly (P < 0.001). Similarly,
SUVmax had prognostic value in combination with nodal status (negative versus positive) or stage (I versus II and III)
(P < 0.001 and P = 0.001, respectively). In hormone receptor–positive disease, SUVmax remained a significant prognostic
factor for RFS based on multivariate analysis.
Conclusions: Our results highlight the prognostic value of FDG-PET in prediction of tumor relapse for patients with breast
cancer. Particularly in patients with hormone receptor–positive disease, the tumor metabolic information provided by
FDG-PET is more significantly correlated with prognosis than tumor burden.Introduction
Tumor burden, represented by tumor size and the
number of involved lymph nodes, is the most important
prognostic factor for breast cancer recurrence [1,2]
because advanced-stage tumors are more likely to have
distant metastases. In the genomics era, rapid advances
in translational research have greatly improved our
understanding of breast cancer biology. This work
provides us with the tools that can identify intrinsic
subtypes of breast cancer and discriminate a prognosis* Correspondence: gsjjoon@yuhs.ac
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unless otherwise stated.according to subtype [3], highlighting the clinical
availability of tumor biology in breast cancer prognosis
[4,5]. These studies provide evidence that small tumors
with undesirable biology can lead to a worse prognosis
than large tumors with favorable biology. Therefore, to
deliver more effective personalized medical treatment to
individual patients, there is an increasing need to evaluate
cancer with tumor biology integration, as well as simple
anatomical staging.
18F-fluorodexoyglucose positron emission tomography
(FDG-PET) is a useful tool in the prediction of tumor
recurrence, as well as for providing relevant anatomical
information, because this imaging modality reflects
tumor biology well [6,7]. It is one of the new tools thatis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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The degree of FDG uptake reflects the metabolic
characteristics of tumors and can be used as a prognostic
factor in various malignancies. In breast cancer, studies
have shown the contribution of tumor biology to
increased FDG uptake [8-10] and have demonstrated
that FDG uptake is associated with aggressive tumor
characteristics [11,12].
As like other molecular markers were compared or
integrated with tumor burden, we wondered whether
the prognostic power of current clinical parameters
improves when the biologic information of FDG-PET
is combined with them. In this retrospective study, we
evaluated the potential of FDG uptake as a prognostic
indicator in breast cancer as compared to, and in
combination with, tumor burden.
Methods
Patient selection
Between April 2004 and May 2009, 1,053 women
consecutively underwent surgery for breast cancer at
our institution. Of these 1,053 patients, 835 underwent
preoperative FDG-PET as a part of their routineFigure 1 CONSORT chart outlining the study plan. DCIS, Ductal carcino
tomography; FISH, Fluorescence in situ hybridization; HER2, Human epidermpreoperative staging. Patients were excluded on the basis
of the following criteria: known bilateral breast cancer
(n = 31), preoperative chemotherapy (because chemo-
therapy can affect tumor characteristics related to FDG
uptake) (n = 94), ductal carcinoma in situ (n = 135) and
distant metastases at initial assessment (n = 42). Among
these patients, 501 women of interest were identified.
Patients missing data for any immunohistochemical
marker were excluded (n = 3). Patients with an immuno-
histochemistry (IHC) scores of 2+ for human epidermal
growth factor receptor 2 (HER2), but without fluorescence
in situ hybridization (FISH) results for HER2 amplifica-
tion, were also excluded (n = 2). Data for the remaining
496 patients were entered into the analysis (Figure 1).
For the immunohistochemical study of four markers,
formalin-fixed, paraffin-embedded tissue sections obtained
from the surgical specimens were stained with appropriate
antibodies for estrogen receptor (ER) (Novocastra; Leica
Microsystems, Newcastle upon Tyne, UK), progesterone
receptor (PR) (Novocastra; Leica Microsystems), HER2
(Ventana Medical Systems, Tucson, AZ, USA) and Ki-67
(MIB-1; Dako, Glostrup, Denmark). For HER2 evaluation,
membranous staining was graded with a score of 0, 1+,ma in situ; FDG-PET, 18F-fluorodeoxyglucose positron emission
al growth factor receptor 2; IHC Immunohistochemistry.
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with a score of 3+ and negative with a score of 0 or 1+.
Tumors with a score of 2+ were sent for FISH testing
performed using the PathVysion HER-2 DNA Probe Kit
(Abbott Molecular, Des Plaines, IL, USA).
The staging was performed according to the American
Joint Committee on Cancer (AJCC) system [14]. The
Elston-Ellis modification of the Scarff-Bloom-Richardson
grading system was used for tumor grading. Adjuvant
systemic therapy and/or radiotherapy were administered
according to the standard guidelines based on patient
age, primary tumor characteristics and axillary lymph
node status. Endocrine therapy was given to patients
whose tumors were positive for hormone receptor
expression. The follow-up protocol included planned
regular visits every 6 months, and missed appointments
were followed by telephone calls to minimize the number
of patients lost to follow-up and improve the accuracy of
the survival data. The final update to the clinical database
was made in December 2013.
The institutional review board (IRB) of Gangnam
Severance Hospital, Yonsei University, Seoul, Korea,
approved the study in accordance with Good Clinical
Practice guidelines and the Declaration of Helsinki.
The IRB granted a waiver of written documentation
of informed consent from all participants because of
the retrospective study design.
18F-fluorodeoxyglucose positron emission tomography
Prior to undergoing FDG-PET, each patient was asked to fast
for a minimum of 8 hours, and blood glucose levels were
controlled to <130 mg/dl. Patients received an intravenous
injection of 18F-FDG (0.14 MBq) in the arm contralateral to
the primary tumor. Sixty minutes after injection of 18F-FDG,
whole-body emission scans were obtained using a Philips
Allegro PET camera (Philips Medical Systems, Cleveland,
OH, USA). Scans were obtained with the patient in the
supine position with the arms raised. Attenuation-corrected
transaxial images were reconstructed with an iterative
transmission algorithm (row-action maximum likelihood
three-dimensional protocol) using a three-dimensional image
filter in a 128 × 128 matrix. For semiquantitative evaluations,
maximum standardized uptake value (SUVmax) was
calculated by measuring the 18F-FDG absorption by tumors
in the region of interest (ROI) using the following equation:
SUVmax = (maximal radioactivity concentration in the
ROI (μCi/g)/injected dose (μCi)/patient’s weight (kg)). All
FDG-PET scans were reviewed by two nuclear medicine
radiologists who were blinded to survival data. SUVmax
was obtained at the time of the imaging procedure.
Statistical analysis
The cutoff point of SUVmax was obtained by using the
time-dependent receiver operating characteristic (ROC)curve. Age is presented in the study as median value
with a range and was compared by the Mann-Whitney
U test. Discrete variables were compared by performing
a χ2 test. The primary endpoint was recurrence-free sur-
vival (RFS), which was measured from the date of the
first curative surgery to the date of the first tumor recur-
rence, including locoregional recurrence or distant me-
tastasis or death. Breast cancer–specific survival (BCSS)
was measured from the date of the first curative surgery
to the date of the last follow-up or until death due to
breast cancer during the follow-up period. The Kaplan-
Meier method was utilized to estimate RFS or BCSS.
Using Harrell c-statistics [15], the concordance index (c-
index) was calculated to measure the concordance for
time-to event data, in which increasing values between
0.5 and 1.0 indicated improved prediction. The signifi-
cant prognostic factors associated with RFS were se-
lected based on the c-index (Additional file 1). The Cox
proportional hazards regression model was used for
multivariable survival analysis. To assess the additional
prognostic value of SUVmax, we used changes in the like-
lihood ratio values (LR − Δχ2) to quantitatively measure
the relative amount of information for SUVmax com-
pared to the model without SUVmax. The cutoff value of
young age was defined as 35 years in accordance with a
previous Korean study [16]. SPSS version 18 (SPSS,
Chicago, IL, USA) and R [17] were used to perform
these analyses. Statistical significance was defined by a
P-value <0.05 or a 95% confidence interval (CI).
Results
Definition of cutoff point for maximum standardized
uptake value
The cutoff point of SUVmax was obtained using the
time-dependent ROC. The time-dependent ROC curve
for SUVmax in relation to RFS yielded an area under the
curve of 0.673 (95% CI, 0.588 to 0.753) (Additional file 2).
Youden’s index was the highest for SUVmax of 4.2. Consid-
ering the clinical application, we defined the SUVmax cut-
off as 4.
Patient characteristics
A total of 496 patients with breast cancer were included
in the analysis. The median age of the cohort was
48 years (range, 25-80 years). The median and mean
SUVmax were 4.3 ± 3.1 and 3.2 (range, 0.3-32.9), respect-
ively. When patients were divided into two groups ac-
cording to SUVmax, these groups differed significantly in
T stage, N stage, AJCC stage, which represent tumor
burden. They also differed in characteristics reflecting
tumor biology, including histologic grade, ER, PR,
HER2, and Ki67. In considering the distribution of
tumor subtypes, the group with high SUVmax had a
higher rate of luminal B, HER2, and triple-negative
Table 1 Baseline characteristics according to maximum standardized uptake valuesa
Characteristics All patients High SUV Low SUV P-valueb
Age at diagnosis, yr 0.698
Median (range) 48 (25 to 80) 48 (25 to 79) 49 (28 to 80)
Histology <0.001
Invasive ductal carcinoma 416 (83.9) 173 (87.8) 243 (81.3)
Invasive lobular carcinoma 22 (4.4) 1 (0.5) 21 (7.0)
Mucinous carcinoma 13 (2.6) 2 (1.0) 11 (3.7)
Tubular carcinoma 6 (1.2) 0 (0.0) 6 (2.0)
Medullary carcinoma 4 (0.8) 4 (0.8) 0 (0.0)
Other invasive carcinoma 35 (7.7) 17 (8.6) 18 (6.0)
T classification <0.001
T1 270 (54.4) 68 (34.5) 202 (67.6)
T2 217 (43.8) 126 (64.0) 91 (30.4)
T3 9 (1.8) 3 (1.5) 6 (2.0)
N classification 0.016
N0 329 (66.3) 115 (58.4) 214 (71.6)
N1 123 (24.8) 59 (29.9) 64 (21.4)
N2 30 (6.0) 17 (8.6) 13 (4.3)
N3 14 (2.8) 6 (3.0) 8 (2.7)
AJCC stage <0.001
I 200 (40.3) 42 (21.3) 158 (52.8)
II 252 (50.8) 131 (66.5) 121 (40.5)
III 44 (8.9) 24 (12.2) 20 (6.7)
Histologic gradec <0.001
1 157 (35.0) 43 (22.8) 114 (44.0)
2 199 (44.4) 78 (41.3) 121 (46.7)
3 92 (20.5) 68 (36.0) 24 (9.3)
ER 0.001
Positive 304 (61.3) 102 (51.8) 202 (67.6)
Negative 192 (38.7) 95 (48.2) 97 (32.4)
PR 0.005
Positive 293 (59.1) 97 (49.2) 196 (65.6)
Negative 203 (40.9) 100 (50.8) 103 (34.4)
HER-2d <0.001
Positive 127 (25.6) 72 (36.5) 55 (18.4)
Negative 369 (74.4) 125 (63.5) 244 (81.6)
Ki67 <0.001
High 102 (20.6) 64 (32.5) 38 (12.7)
Low 394 (79.4) 133(67.5) 261 (87.3)
Subtypes <0.001
Luminal A 257 (51.8) 71 (36.0) 186 (62.2)
Luminal B 71 (14.4) 39 (19.8) 32 (10.7)
HER2 83 (16.7) 45 (22.8) 38 (12.7)
Triple negative 85 (17.1) 42 (21.3) 43 (14.4)
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Table 1 Baseline characteristics according to maximum standardized uptake valuesa (Continued)
Surgery type 0.043
Mastectomy 352 (70.9) 150 (76.1) 202 (67.5)
Breast-conserving surgery 144 (29.1) 47 (24.9) 97 (32.5)
Adjuvant chemotherapy <0.001
Yes 347 (70.0) 162 (82.2) 185 (61.9)
No 149 (30.0) 35 (17.8) 114 (38.1)
Adjuvant endocrine therapy 0.001
Yes 332 (66.9) 114 (57.9) 218 (72.9)
No 164 (33.1) 83 (42.1) 81 (27.1)
Adjuvant radiotherapy 0.915
Yes 189 (38.1) 74 (37.6) 115 (38.5)
No 307 (61.9) 123 (62.4) 184 (61.5)
aAJCC, American Joint Committee on Cancer; ER, Estrogen receptor; HER2, Human epidermal growth factor receptor 2; PR, Progesterone receptor; SUVmax,
Maximum standardized uptake value. Data are number of patients (%), except for age. bχ2 test. cData with missing values. dHER2 positivity was defined as a
3+ score on immunohistochemistry or amplification on fluorescence in situ hybridization.
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luminal A subtype was relatively low in the group with
high SUVmax (Table 1). A higher rate of mastectomy was
noted in the group with high SUVmax (Table 1).
Survival outcome
At a median follow-up of 6.03 years, tumors had recurred
in 40 patients. There were 13 patients with locoregional
recurrences, 25 with distant metastases and 2 with
combined local recurrence and distant metastases.
During the follow-up period, 11 deaths occurred, 8
of which were breast cancer–specific and 3 of which
were not breast cancer–specific. The probability of
RFS at 6 years was 95.6% for patients with low SUVmax
and 86.8% for patients with high SUVmax. High SUVmax
was significantly predictive of decreased RFS (P < 0.001 by
log-rank test) (Figure 2A). Furthermore, patients with high
SUVmax showed a reduced BCSS (P = 0.007 by log-rank
test) (Figure 2B). When adjusted for age of diagnosis,
T stage, nodal status and ER status using the Cox
proportional hazards regression model, high SUVmax
was significantly associated with risk of tumor relapse
(hazard ratio, 2.39, 95% CI, 1.20 to 4.76) (Table 2).
For this model, the Harrell c-index was 0.745. The c-index
for the multivariate model without SUVmax was 0.724.
The LR-Δχ2 showed a significant improvement of the
additional prognostic utility of SUVmax.
Prognostic value of a combined maximum standardized
uptake values with tumor burden
Four patient groups were classified according to SUVmax
and tumor size: (1) tumor size ≤2 cm and SUVmax <4; (2)
tumor size >2 cm and SUVmax <4; (3) tumor size ≤2 cm
and SUVmax ≥4; and (4) tumor size >2 cm and SUVmax ≥4.
The RFS of the four groups differed significantly (P < 0.001)(Figure 3A). Within the groups of large tumor size (>2 cm)
and small tumor size (≤2 cm), RFS differed significantly
according to the SUVmax (P = 0.049 and P = 0.009,
respectively). Conversely, within the groups of high
SUVmax and low SUVmax, RFS did not differ according to
tumor size (P = 0.350 and P = 0.096, respectively).
Furthermore, SUVmax was significantly predictive of RFS
in combination with nodal status (P < 0.001) (Figure 3B).
Node-positive patients with high SUVmax had worse out-
comes, whereas node-negative patients with low SUVmax
had better outcomes. Similarly, SUVmax combined with
stage was significantly correlated with RFS (P = 0.001)
(Figure 3C).
Maximum standardized uptake values in luminal breast
cancer
After the patients were divided into three subtypes
(luminal, HER2 or triple-negative), multivariate analysis
for RFS was performed in each subtype. In luminal sub-
types, which were defined as hormone receptor–positive
breast cancer (ER-positive and/or PR-positive), SUVmax
was found to be a significant prognostic factor for RFS
based on multivariate analysis (Table 3). However, in
HER2 or triple-negative subtypes, SUVmax was not an
independent prognostic factor (Additional file 3).
The prognostic value of SUVmax combined with tumor
burden was also assessed in hormone receptor–positive
breast cancer. When the patients were classified into
four groups according to both combined factors, RFS
differed significantly (P < 0.001) (Figure 4A). There was
no difference in RFS when patients were stratified by
tumor size within the groups with high SUVmax and
low SUVmax (P = 0.950 and P = 0.688, respectively).
However, within the groups with small tumor sizes
(≤2 cm), a significantly reduced RFS was found in
Figure 2 Kaplan-Meier plots for disease-free survival and breast cancer–specific survival. (A) Recurrence-free survival (P = 0.001). (B) Breast
cancer–specific survival (P = 0.007). SUVmax, Maximum standardized uptake value. All P-values were calculated by the log-rank test.
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large tumor sizes (>2 cm), RFS did not differ significantly
according to SUVmax (P = 0.065), possibly due to the
limited number of patients (n = 122).
In luminal breast cancer, SUVmax was still predictive
of RFS in combination with nodal status (negative vs.positive) and stage (I vs. II and III) (P < 0.006 and P = 0.029,
respectively) (Figure 4B and 4C).
Discussion
The results of our study demonstrate the ability of SUVmax
to predict clinical outcomes in a large cohort of breast
Table 2 Multivariate analysis for recurrence-free survival
using Cox proportional hazards regression model
Factors Hazard ratio 95% CI P-value
Age 0.144
>35 yr Reference
≤35 yr 1.86 0.81 to 4.25
Tumor size 0.151
≤2 cm Reference
>2 cm 1.63 0.84 to 3.19
Nodal status 0.038
Negative Reference
Positive 1.93 1.04 to 3.59
Estrogen receptor status 0.021
Positive Reference
Negative 2.19 1.12 to 4.27
HER2 status 0.389
Negative Reference




High (≥4) 2.39 1.20 to 4.76
aCI, Confidence interval; HER2, Human epidermal growth factor receptor-2;
SUVmax, Maximum standardized uptake value.
bP = 0.009 and χ2 = 25.41 for
the comparison with the analysis without SUVmax (by the likelihood ratio test).
Figure 3 Kaplan-Meier plots for recurrence-free survival
according to combined factors with tumor burden and
SUVmax. (A) Tumor size (P < 0.001) (B) Node status (P < 0.001)
(C) Stage (P = 0.001). SUVmax, Maximum standardized uptake
value. All P-values were calculated by the log-rank test.
Ahn et al. Breast Cancer Research  (2014) 16:502 Page 7 of 10cancer patients who underwent FDG-PET. SUVmax carried
independent prognostic significance in multivariate analysis
for prediction of tumor relapse. Attempts to validate FDG
uptake as a prognostic indicator in breast cancer have been
made in previous studies [18-20]. However, failure to be
validated as an independent prognostic factor [18],
small number of patients [19] and analysis based on a
web-accessible risk-assessment model (Adjuvant! Online)
[20] were limitations. Despite these limitations, those
studies provided evidence that that FDG uptake has
potential as a prognostic marker in breast cancer, which
seems reasonable because tumors with increased glucose
uptake show aggressive tumor behaviors and high prolifer-
ative propensities [8-10]. Other studies have consistently
shown that breast cancer with a high SUVmax is associated
with ER negativity, high histologic grade, high Ki67 and
the triple-negative subtype [10-12], which is consistent
with our data (Table 1). In support of the clinical signifi-
cance of tumor biology–associated glucose metabolism
are recent studies showing that several signaling pathways
implicated in cell proliferation and tumor progression also
regulate metabolic pathways [21-24].
Particularly in the survival analyses using a combined
factor with SUVmax and tumor burden, SUVmax showed
a superior prediction of RFS in breast cancer compared
with clinical tumor load. After four groups were formed
Table 3 Multivariate analysis for recurrence-free survival
using Cox proportional hazards regression model in
hormone receptor–positive diseasea
Factors Hazard ratio 95% CI P-value
Age 0.001
>35 yr Reference
≤35 yr 6.61 2.23 to 19.57
Tumor size 0.706
≤2 cm Reference
>2 cm 0.815 0.28 to 2.35
Nodal status 0.451
Negative Reference
Positive 1.49 0.53 to 4.21
HER2 status 0.277
Negative Reference
Positive 1.87 0.61 to 5.77
SUVmax 0.033
Low (<4) Reference
High (≥4) 3.56 1.11 to 11.41
aCI, Confidence interval; HER2, Human epidermal growth factor receptor 2; SUVmax,
Maximum standardized uptake value.
Figure 4 Kaplan-Meier plots for recurrence-free survival
according to a combined factor that includes both tumor burden
and SUVmax in hormone receptor-positive cancer. (A) Tumor size
(P = 0.028) (B) Node status (P = 0.006) (C) Stage (P = 0.029). SUVmax,
Maximum standardized uptake value. All P-values were calculated by
the log-rank test.
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high or low SUVmax, tumor size did not provide add-
itional prognostic differentiation (Figure 3A). However,
within the groups with large or small tumor size, SUV-
max improved the prediction of RFS. Similar results were
seen when SUVmax was combined with nodal status or
AJCC stage (Figures 3B and 3C). These findings suggest
that when tumor biology is considered in addition to
clinical tumor burden, prediction of breast cancer prog-
nosis can be improved. SUVmax could provide powerful
prognostic information about tumor relapse that is su-
perior to considering only tumor burden, similar to the
contribution of molecular subtype.
There are established molecular predictors reflecting
tumor biology and predicting prognosis in breast cancer.
Although the reason that the multigene assays are actively
utilized for ER-positive disease has not been fully clarified,
authors of meta-analyses of various multigene breast
cancer signatures concluded that the prognostic values of
the signatures are comparable when evaluated in hormone
receptor–positive breast cancers, presumably due to the
fact that the proliferation modules within these diverse
gene signatures are a common driving force behind their
overall prognostic performance [25,26]. By contrast,
hormone receptor–negative breast cancers are more
proliferative and are usually classified as high risk or
are not the appropriate target population for these
prognostic signatures [25,26]. In the same context, our
results show that the prognostic significance of SUVmax is
distinct for luminal tumors (Table 3, Figure 4).
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was the lowest, whereas the values for the HER2 and
triple-negative subtypes were comparatively higher
(Additional file 4). This finding is concordant with
previous reports comparing SUVmax between the
IHC-defined subtypes [27]. It seems reasonable that
HER2-positive or triple-negative tumors would show
increased accumulation of FDG, because these tumors
have an aggressive phenotype and are associated with
a high rate of proliferation, high Ki67 concentration
and high histologic grades. These associations between
aggressive markers and high SUVmax were concordantly
observed in our study (Table 1). Because HER2-positive or
triple-negative tumors generally show high SUVmax, this
may also lead to a reduced prognostic significance of
SUVmax in these kinds of tumors.
We acknowledge several limitations inherent in
our study’s retrospective design. We were unable to
control for variations in adjuvant therapy that may
have influenced survival outcomes. Compared to the
low SUVmax group, the patients in the high SUVmax
group received more chemotherapy and less endocrine
therapy, likely because they had more advanced
stage disease and ER negativity. The cutoff point for
SUVmax defined within a single cohort also needs to
be validated in an external cohort. However, there
was not a significant difference in the number of
patients who received radiation treatment between
the high SUVmax group and the low SUVmax group.
There was also no survival difference between patients
who received adjuvant chemotherapy or radiotherapy
(Additional file 1).
Conclusions
Our study highlights the prognostic value of FDG-PET
in predicting tumor relapse for breast cancer patients.
We provide evidence supporting the potential utility
of FDG-PET in combination with clinical tumor burden
for the assessment of prognosis as well as evaluation
of tumor location in patients with breast cancer.
These results lay the groundwork for future studies
on the prognostic implication of SUVmax for breast
cancer treatment.Additional files
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